Table 1.
Characteristics of included studies and patientsa
| Author; Year | Recruitment period | Study design; Settings | Country/Region | Sample size | Age (years) | Male; n (%) | Comorbidities; n (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypertension | Diabetes | CVD | CKD | COPD | |||||||
| Assaad [24] | 1 Mar—15 Apr 2020 | Retrospective; Single center | France | 55 | 63.8 ± 2.2 | 26 (47.3) | NR | NR | NR | NR | NR |
| Dai [33] | 1 Jan—24 Feb 2020 | Retrospective; Multicenter | China | 105 | 64 (IQR: 14) | 57 (54.3) | 30 (28.6) | 7 (6.7) | 12 (11.4) | 6 (5.7) | NR |
| Garassino [34]b | 26 Mar—12 Apr 2020 | Retrospective; Multicenter | Asia, Europe, USA | 200 | 68 (61.8–75.0) | 141 (70.5) | 93 (47.0) | 29 (15.0) | 30 (15.0) | 15 (8.0) | 51 (26.0) |
| Gonzalez-Cao [25] | 1 Apr—17 May 2020 | Retrospective; Multicenter | Spain | 50 | 69 (Range: 6–94) | 27 (54.0) | NR | NR | NR | NR | NR |
| Lara [29] | 1 Mar—22 Apr 2020 | Retrospective; Multicenter | USA | 121 | 64 (51–73) | 0 (0.0) | 69 (57.0) | 38 (31.4) | 8 (6.6) | 9 (7.4) | 4 (3.3) |
| Lee [26, 53]c | 18 Mar—26 Apr 2020 | Prospective; Multicenter | UK | 800 | 69 (59–76) | 449 (56.1) | 247 (30.9) | 131 (16.4) | 109 (13.6) | NR | 61 (7.6) |
| Luo [30, 54]d | 12 Mar—13 Apr 2020 | Retrospective; Single center | USA | 69 | 69 (Range: 31–91) | 33 (47.8) | 38 (55.1) | 21 (30.4) | 5 (7.2) | NR | 12 (17.4) |
| Pinato [27]b,c | 26 Feb—1 Apr 2020 | Retrospective; Multicenter | Europe | 890 | 68.0 ± 12.8 | 503 (56.5) | 386 (43.4) | 181 (20.3) | 128 (14.4) | 77 (8.7) | 119 (13.4) |
| Robilotti [31]d | 10 Mar—7 Apr 2020 | Retrospective; Single center | USA | 423 | NR | 212 (50.1) | 214 (50.7) | 84 (19.9) | 84 (19.9) | 36 (8.5) | 29 (6.9) |
| Tyan [32] | 20 Mar—3 Jun 2020 | Retrospective case–control; Multicenter | USA | 50 | 72 (Range: 45–83) vs 68 (Range: 36–87) | 28 (56.0) | 29 (58.0) | 12 (24.0) | 14 (28.0) | NR | 13 (26.0) |
| Yarza [28] | 9 Mar—19 Apr 2020 | Retrospective; Single center | Spain | 63 | 66 ± 10.93 | 34 (54,0) | 33 (52.4) | 11 (17.5) | 12 (19.0) | 5 (7.9) | 14 (22.2) |
| Author; Year | Cancer types; n (%) | Adjuvant therapy; n(%) | ICI | Outcomes | |||||
|---|---|---|---|---|---|---|---|---|---|
| Hematologic | Solid tumor | Metastatic | Last ICI dose to COVID-19 diagnosis (days) | Anti-PD-1 | Anti-CTLA-4 | Anti-PD-L1 | |||
| Assaad [24] | 20 (36.4) | 35 (63.6) | 29 (52.7) |
Chemotherapy: 18 (32.7) Other immunotherapy: 6 (10.9) Targeted therapy: 6 (10.9) |
Max: 30 | 3 (5.5) | 0 (0.0) | 3 (5.5) | Mortality |
| Dai [33] | 9 (8.6) | 96 (91.4) | 17 (16.2) |
Chemotherapy: 3 (2.9) Targeted therapy: 1 (1.0) |
40 ± 40.5 | 6 (5.7) | 0 (0.0) | 0 (0.0) | ICU admission, Invasive ventilation, Mortality, Severity (AKI, ARDS, DIC, rhabdomyolysis, septic shock) |
| Garassino [34]b | 0 (0.0) | 200 (100) | 147 (74.0) |
Cementoplasty: 1 (0.5) Chemotherapy: 24 (12) Radiotherapy: 3 (1.5) Targeted therapy: 2 (1.0) |
NR | NR | NR | NR | Hospitalization, ICU admission, Mechanical ventilation, Mortality, Prolonged hospitalization (> 8 days) |
| Gonzalez-Cao M [25] | 0 (0.0) | 50 (100) | 36 (72.0) | 0 (0.0) | 56 | 22 (44) | 0 (0.0) | 0 (0.0) | Hospitalization, ICU admission, Mortality, Severity (ARDS, sepsis, septic shock, severe COVID-19) |
| Lara [29] | 0 (0.0) | 121 (100) | NR |
Chemotherapy: 35 (28.9) Hormone therapy: 9 (7.4) Radiotherapy: 9 (7.4) Surgery: 11 (9.1) Targeted therapy: 13 (10.7) |
25.3 ± 14.6 | 4 (3.3) | 0 (0.0) | 0 (0.0) | Hospitalization, Mortality |
| Lee [26, 53]c | 169 (21.1) | 584 (73.0) | 347 (43.4) | NR | Max: 28 | 0 (0.0) | 44 (5.5) | 44 (5.5) | Mortality |
| Luo [30, 54]d | 0 (0.0) | 69 (100) | NR | Surgery/Radiotherapy: 32 (46.4) | Median: 45 (Range: 4–820) | 41 (59) | 0 (0.0) | 0 (0.0) | Hospitalization, Mortality, Severity (ICU admission, invasive ventilation) |
| Pinato [27]b,c | 137 (15.4) | 753 (84.6) | 351 (39.4) |
Chemotherapy: 164 (69.8) Hormone therapy: 48 (20.4) Targeted therapy: 41 (17.4) |
Max: 28 | NR | NR | NR | Mortality, Severity (Complications, i.e., ARDS, sepsis, septic shock) |
| Robilotti [31]d | 102 (24.1) | 184 (43.5) | 238 (56.3) | NR | 24.4 20.8 | 25 (5.9) | 2 (0.5) | 5 (1.2) | Hospitalization, Mortality, Severity (high-flow oxygen supplementation mechanical ventilation) (30 days) |
| Tyan [32] | 10 (20.0) | 40 (80.0) | NR | NR | 29 (Range: 0–328) | 20 (80.0) | 1 (4.0) | 4 (16.0) | Hospitalization, ICU admission, Mortality |
| Yarza [28] | 0 (0.0) | 63 (100) | 52 (82.5) |
Chemotherapy: 36 (57.1) Hormone therapy: 10 (15.9) Targeted therapy: 7 (11.1) |
Max: 28 | NR | NR | NR | Mortality, Severity (ARDS) |
aUnless explicitly stated, data are presented in n (%), mean standard deviation, or median (interquartile range)
bOverlapping populations were observed between Garassino [34] and Pinato [27]
cOverlapping populations were observed between Lee [26, 53] and Pinato [27]
dOverlapping populations were observed between Robilotti [31] and Luo [30, 54]
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CTLA-4, cytotoxic T-lymphocyte associated protein 4; CVD, cardiovascular disease; DIC, disseminated intravascular coagulation; ICI, immune checkpoint inhibitor; ICU, intensive care unit; IQR, interquartile range; PD-1, programmed cell death protein 1; PD-L1, PD-1 ligand 1; NR, not reported; UK, United Kingdom; USA, United States of America